NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, focuses on exploiting the promising scientific results of NFL-101, its drug candidate for smoking cessation, with two initiatives: the submission of a scientific article and a presentation given at the annual congress of the Nicotine and Tobacco Research Society (SRNT) at the end of March.
Submission of a scientific article co-signed by the CEA, the Georges Pompidou European Hospital and NFL-Biosciences
Just two months after obtaining the results, the CEA recently submitted an article on the results of the study of the mechanism of action of NFL-101 conducted with NFL Biosciences in 2023 to an international scientific journal. The research presented was supplemented by previous work from the Hôpital Européen Georges Pompidou (HEGP). This synergy with different prestigious institutions aims to strengthen the impact and scope of the results obtained. The publication of this article is hoped for during the spring after acceptance by the scientific review committee of the journal. This work can then be highlighted at future scientific conferences.